Maspin, SCCA1/2 and hurpin were identified by cDNA microarray analyses as dramatically differentially expressed transcripts in primary non-small cell lung cancer (NSCLC). These sequences are located within a 10-gene serpin cluster on 18q21.3. Using comparative RT-PCR, we have investigated the expression of each of these serpins, including their flanking loci, in an independent NSCLC series. Whereas six of the genes (maspin, SCCA1, SCCA2, hurpin, megsin and pAI-2) were commonly differentially expressed in primary lesions, each significantly more often in squamous cell tumours, maspin was identified as the most frequently overrepresented sequence in both squamous cell carcinoma and adenocarcinoma. Using a well-characterized monoclonal antibody, we have shown strong maspin expression in tumour protein extracts, detected multiple isoforms of the 42 kDa protein and shown that maspin is localized specifically to the tumour cells within neoplastic lesions. In contrast, most cells in non-neoplastic lung tissue appear not to express the gene, with the exception of the multipotent basal epithelial cells that line the bronchial airway. These reserve cells generally show strong predominantly nuclear localization of maspin. Strong nuclear expression of maspin within primary tumour cells is correlated with increased survival (P ¼ 0.05) and a longer remission duration (P ¼ 0.02) in resectable-staged patients. However, within the airways of cancer patients and somewhat in contrast to this observation, such expression was more frequently detected in the superficial cells of preneoplastic over non-neoplastic epithelia (Po0.0001), consistent with a role for the protein in early neoplasia.
Introduction
Lung cancer is the leading cause of cancerrelated death. At presentation, most patients have advanced disseminated disease for which no curative treatment is available. The 5-year survival rate for lung cancer patients in Europe is approximately 10% (Bray et al., 2002) , a figure that has not significantly improved in the last 40-50 years. The identification of new molecular targets with application in the early detection and effective treatment of lung cancer is therefore of paramount importance.
To this end, we have compared gene expression patterns between 39 resected primary human nonsmall cell lung cancers (NSCLCs) and matched histologically normal lung tissue using cDNA microarray profiling (Heighway et al., 2002) . Among the most frequently and significantly tumour overrepresented sequences were maspin (SERPINB5) and squamous cell carcinoma antigen 1 (SCCA1). These serine protease inhibitors (serpins), located in a cluster of 10 serpins on chromosome 18q21.3 (Figure 1 ), were found to be significantly over-represented in 18/37 and 11/37 tumours, respectively. Another serpin from this cluster, hurpin, was overrepresented in 8/37 tumours. These microarray expression analyses were subsequently validated by representative comparative multiplex RT-PCR (cmRT-PCR) assays.
The serpin cluster on 18q21.3 lies distal to the B-cell lymphoma, translocation-targeted BCL2 gene. While immunohistochemical studies have suggested that BCL2 is expressed in 20-30% of NSCLC (Pezzella et al., 1993; Borner et al., 1999) , our microarray analysis indicated that the transcripts of this gene were not frequently nor dramatically over-represented above normal tissue in the analysed samples. In contrast, the identification of maspin as an NSCLC over-represented sequence was surprising given its assumed role as a tumour suppressor. While the specific cellular function(s) of this putative serpin is not currently clear, downregulation of the gene is thought to occur during the development of breast cancer (Maass et al., 2001b) . Furthermore, lack of maspin expression has been correlated in a number of studies with an increased tendency of certain primary tumours to metastasize (Maass et al., 2001a; Yasumatsu et al., 2001) . Complimenting such data, functional studies have indicated that maspin expression can indeed suppress invasion and metastasis in model systems (Shi et al., 2001; Abraham et al., 2003) . However, in contrast to these observations, maspin expression has been strongly correlated with reduced survival in breast cancer patients (Umekita et al., 2002) and shown to be a negative prognostic indicator in ovarian carcinoma (Sood et al., 2002) . Interestingly, Pierson et al. (2002) have recently suggested that maspin upregulation precedes the critical transition from premalignant lesion to invasive prostate cancer.
Our intention in this study was to investigate the pattern of expression of maspin, SCCA1/2, hurpin and the other serpin genes within the 18q21.3 cluster in an independent series of NSCLCs. This analysis also included the nonserpin flanking genes, between and including, BCL2 and cadherin 7 (CDH7). Having identified maspin as the most frequently tumour over-represented sequence in the region, we analysed corresponding protein levels by Western blotting and we confirmed the tumour cell localization of expression by immunohistochemistry (IHC). We subsequently extended the IHC investigations to encompass an evaluation of maspin expression in tumours and normal and preneoplastic bronchial epithelia from multiple tumour-free sites of NSCLC patients.
Results

Expression of serpins in the 18q21. 3 cluster
In order to avoid possible bias in the evaluation of the significance and frequency of expression differences between tumours and normal tissues for genes highlighted through prior microarray transcript analyses, RNA and protein were extracted from an independent series of resected tumours and matched normal lung tissues of 35 NSCLC patients. The expression of the 10 serpins in the chromosome 18q21 cluster (Figure 1 ) was investigated in this series, initially by RT-PCR and subsequently by cmRT-PCR using endogenous gene expression controls previously identified as sequences not-differentially expressed in lung carcinoma versus matched normal tissue (Heighway et al., 2002) . Yukopin, epipin and bomapin transcripts were not detected in either the normal lung or tumour tissue of any of the patients investigated. For these genes, RT-PCR primers were subsequently shown to be effective through amplification of specific products from one or more normal tissues from a 16-sample cDNA panel. The pI8 gene showed approximately equal expression in both the normal and tumour samples of each patient (cmRT-PCR).
Maspin -either singly or in combination with one or more of hurpin, SCCA1/2, megsin or pAI-2 -showed differential expression between the normal and tumour samples in at least 26/35 patients (Table 1: representative cmRT-PCR gel images presented as supplementary data on www.roycastle.org/research/presentations.htm). In many cases, transcripts were detected only in the tumour tissue of the patient. To quantify expression, the relative levels of test over endogenous control gene in each reaction were measured on an Agilent 2100 Bioanalyser DNA running a DNA 1000 chip with the value obtained from the tumour divided by that from the normal tissue to obtain a fold-difference. In many cases, the value derived was infinite, reflecting the lack of detected expression of the test gene in the normal component. The use of this procedure semiquantitatively simplified the data and facilitated a lesion-bylesion analysis of regional gene expression (Table 1) .
Maspin was over-represented in the tumour, compared to matched normal lung, in 26/35 (74%) of the patients investigated; hurpin in 14/35 (40%) patients; SCCA1/2 in 15/35 (43%); megsin in 19/35 (54%) and pAI-2 in 12/35 (34%) of tumours. Considering disease pathology, the expression of all five genes was more highly associated with squamous carcinomas than adenocarcinomas (Po0.01, 0.01, 0.01, 0.01 and 0.02 for maspin, hurpin, SCCA1/2, megsin and pAI-2, respectively). Interestingly, 8/15 squamous carcinomas but 0/18 adenocarcinomas showed over-representation of all five of these genes. Conversely, 8/18 adenocarcinomas showed no over-representation of any of the five. In all, 15/15 squamous cell carcinomas showed overrepresentation of one or more of the genes (minimally, maspin) compared to 10/18 adenocarcinomas. If maspin transcripts were not detected in the tumour sample Figure 1 Positional map of the genes within and flanking the 18q21.3 serpin cluster. Left-hand arrows indicate the predicted direction of transcription. NSCLC over-represented serpin genes are highlighted in red (9/18 NSCLC), then none of the other four genes were scored as over-represented in that lesion.
RFLP analysis of SCCA1 and SCCA2 expression
The genes for SCCA1 and SCCA2 are adjacent to each other in the human genome and share 98% nucleotide sequence similarity (Suminami et al., 1991) . The cmRT-PCR primers (annealing to matching regions of 100% sequence identity) were initially designed to amplify both SCCA1 and 2 simultaneously. Sequence differences between the two genes were subsequently used to design an RFLP-type analysis to determine the relative expression of SCCA1 and SCCA2 in the 15 patients where SCCA1/2 was over-represented in the tumour compared to the normal lung. Relative expression was also investigated in three matched normal lung tissue samples where expression was detected, as well as a further three patients who showed approximately equal levels of SCCA1/2 in their normal and tumour samples.
Amplification of SCCA1 and 2 transcripts by RT-PCR, using the rflpSCCA1/2 primer set, gave a 729 bp PCR product from both genes. Following digestion with EcoRV, the SCCA1 product was digested to fragments of 252 and 477 bp. The SCCA2 product remained at 729 bp. Digested PCR products were run on 2.5% agarose gels (see Figure 2 ) and on an Agilent 2100 Bioanalyser DNA 1000 chip to quantify the relative amounts of SCCA1 and 2 in each sample. The relative peak heights of SCCA2 to SCCA1 were calculated as a percentage (see Table 2 ). In 18/18 tumours investigated (including 12 squamous carcinomas, five adenocarcinomas and one large cell carcinoma), both SCCA1 and SCCA2 transcripts were detected in the tumour, with SCCA1 being predominant in all but one patient (200). In the six normal lung samples investigated, only SCCA1 transcripts were detected.
Expression of genes flanking the serpin cluster
The expression of four genes flanking the serpin cluster, namely BCL2, follicular lymphoma variant translocation 1 (FVT1), vacuolar protein sorting factor 4B (SKD1) and cadherin 7 (CDH7) was investigated by cmRT-PCR. Marginal over-representation of BCL2 was detected in only 2/35 (5.7%) patients investigated. Levels of FVT1 and SKD1 expression were uniform between the tumour and normal samples in each patient. CDH7 transcripts were not detected. Transcripts were scored as tumour over-represented (red boxes) or under-represented (green boxes). In many cases, were genes were scored as under-represented in tumours, this was with respect to lowlevel target gene amplification from normal tissue samples. Black boxes represent tissues where transcripts were either balanced or not detected in both tissues Figure 2 EcoRV restriction digest analysis of SCCA1 and 2 transcripts amplified using a common primer set. Subsequent product ratios are therefore relative to starting levels in the tissue extracts. SCCA2 transcripts were only detected in tumour tissue. Marker is a FX174/HaeIII digest
Western analysis of maspin levels
The transcript analyses (microarray, RT-PCR) highlighted maspin as being the most frequently tumourover-represented of the 18q21.3 serpins in two independently analysed sets of NSCLC. We consequently focused our attention on this putative tumour suppressor. Using an extensively characterized monoclonal antibody, Pharmingen G167-70, we investigated maspin protein levels by Western blotting, comparing representative matched tumour and normal tissue extracts. No immunoreactive bands were observed in normal lung tissue extracts. In contrast, and in close correlation with the predictions from the transcript data derived from adjacent tissue sections, tumour-encoded proteins showed strong immunoreactivity for a 42 kDa band. Interestingly, a second band of approximately 36 kDa was also reactive with the maspin antibody in most carcinoma samples. In several tumour samples, 2-4 additional isoforms were also observed. Our standard Western protocol included 0.1% (w/v) SDS in the transfer buffer. The omission of SDS from this buffer resulted in the detection of just one single immunoreactive 42 kDa band in most (but not all) tumour samples ( Figure 3 ).
Immunohistochemistry
The expression of maspin was further examined by IHC in a separate series of 48 formalin-fixed paraffinembedded tissues from resectable-staged NSCLC patients. In addition to an analysis of the tumour material, six geographically independent bronchial epithelial sites distant from the primary tumour from 20 of the patients were investigated (120 sites). The aim of this aspect of the study was firstly to ascertain which cell type within the tumour tissue maspin was localized to and to determine whether expression is correlated with clinical outcome. The analysis of multiple normal-tissue sites from a subset of patients allowed us to ask further questions related to the nature and frequency of maspin expression in non-neoplastic (normal or hyperplastic: goblet cell hyperplastic-metaplastic/basal cell hyperplastic/nonspecific hyperplastic) and preneoplastic (squamous metaplastic/squamous dysplastic) bronchial epithelia. Staining intensity was classified as negative, weak (À, þ ) or strong ( þ þ , þ þ þ ) in greater than or less than 5% of cells and as cytoplasmic or nuclear. The stromal cells and lymphocytes were completely negative for maspin expression in all cases. In contrast, 18.8 Figure 3 Western analysis of normal lung (N) and NSCLC tissue (T) extracts. The top line of agarose gel images (a) shows cmRT-PCR data for three paired tissues. Equal amounts of protein extracted from adjacent sections were analysed for maspin immunoreactive proteins (b). Reactive bands were seen under the conditions and exposure times used only in the tumour extracts. Panel c shows the effect of altering the composition of the Western transfer buffer. While two immunoreactive bands are seen in the presence of SDS, only one 42 kDa product is detected using conventional transfer buffer. These data suggest that maspin is present in the tumour extracts as multiple isoforms that perhaps have different biochemical properties 28 tumours (58%) showed strong expression of maspin, 20 tumours (42%) were scored as negative ( Figure 4 ). Protein was localized to both the nucleus and cytoplasm in most cases. As in the RT-PCR analysis, strong maspin expression was more frequently associated with squamous carcinoma (19/20) than adenocarcinoma (10/23: P>0.0001). Strong nuclear expression was associated with a longer remission interval (P ¼ 0.02) and increased overall survival (P ¼ 0.05) ( Figure 5 ). Considering the histologically tumour-free lung tissues analysed (Table 3) , bronchial epithelia were microscopically identified in 115/120 samples (20 patients). These sites were classified as showing non-neoplastic (84), preneoplastic (28) or neoplastic Normal panels a-c show the range of staining patterns seen in histologically normal bronchial epithelia. The most common pattern was one of strong nuclear staining of the basal epithelial cells with superficial cells being negative. However, a small number of hyperplastic epithelia show strong nuclear/cytoplasmic expression of maspin. The remaining panels show preneoplastic epithelial lesions, which commonly show strong staining for maspin. The flanking histologically normal epithelia in the metaplasia and dysplasia panels show a more typical expression pattern (carcinoma in situ, 3) histology. While stromal and other cells were clearly negative at all sites, strong nuclear, usually accompanied by some cytoplasmic, staining for maspin was generally detected in the basal epithelial cells. In contrast, in all normal epithelial sites (11/11) the superficial differentiated columnar epithelial cells were completely negative for maspin (Figure 4 , normal a-c). The same was true for the majority of hyperplastic sites (68/73) but interestingly, a small number of such lesions (5/73) showed strong staining for maspin in the superficial epithelial layer (Figure 4 ). In total, 79/84 (94%) normal/hyperplastic sites were scored as negative for apical nuclear staining for maspin. On the basis of these data, we suggest that maspin expression in nonneoplastic bronchial epithelia is restricted to the basal epithelial cells where it is predominantly nuclearlocalized. In marked contrast to this normal pattern, a significantly different, high frequency (13/28, 46%) of pre-neoplastic epithelia ( Figure 4 ) showed strong nuclear staining for maspin (Po0.0001). In some instances, the adjacent normal epithelia showed a more normal basal epithelia-localized expression (dysplasia panel, Figure 4 ). The frequency of maspin expression in preneoplastic epithelia was similar to that seen in tumours (46 versus 56%, P ¼ 0.47)
Discussion
The serine protease inhibitor (serpin) superfamily includes inhibitors of a number of serine proteases with roles in a variety of cellular processes, including fibrinolysis, cell migration and adhesion, proliferation and inflammation. We have previously reported that maspin, hurpin and SCCA1/2 are over-represented in primary lung tumours (Heighway et al., 2002) . In this study, we have confirmed and extended those earlier microarray-based observations. Our aim was to investigate the expression of the genes in this region in an independent series of NSCLC lesions, considering not only those sequences highlighted in the array analyses, but also others within the immediate genomic locality.
We were able to confirm that maspin, SCCA1, SCCA2 and hurpin were strongly differentially expressed in significant numbers of tumours. We were also able to show that in a number of samples, megsin and pAI-2 were over-represented in NSCLC compared to matched normal lung. Of the other serpins in the 18q21.3 cluster, expression of yukopin, epipin and bomapin was not detected and pI8 expression was balanced between tumour and normal samples. The levels of BCL2, FVT and SKD-1, non-serpin genes flanking the 18q21.3 cluster, were not dramatically altered between tumour and normal lung, although BCL2 showed slight over-representation in tumours of 2/35 patients. Transcripts of CDH7, the most distal gene analysed, were not detected in either normal lung or tumour. The genes that showed frequent differential expression (DE) were therefore interspersed among genes that appear not to be expressed in the tissues Figure 5 Overall survival and remission duration of patients with strong nuclear expression for maspin (n ¼ 28 patients: red line) compared to patients with weak/no detectable nuclear maspin in the primary tumour (n ¼ 20 patients: blue line) It is however interesting to speculate that such a mechanism might contribute to tumour-specific expression given that the region is known to undergo somatic translocations in some B-cell lymphomas. Several of the tumour over-represented genes in this region have previously been implicated in malignancy. Squamous cell carcinoma antigen (SCCA) has been implicated as a circulating tumour marker for squamous cell carcinoma of the cervix, head and neck, lung and oesophagus (Kato, 1992) . SCCA is transcribed from the tandemly repeated genes, SCCA1 and SCCA2, which have 98% sequence identity at the nucleotide level and 92% identity at the amino-acid level (Schneider et al., 1995) . The products of the two genes have different protease targets; SCCA1 inhibits papain-like cysteine proteases (cathepsin S, L and K; Schick et al., 1998) and SCCA2 inhibits chymotrypsin-like serine proteases (e.g. cathepsin G and mast cell chymase; Schick et al., 1997) . Previously, SCCA1 and 2 have been reported to be coexpressed in moderately-and well-differentiated squamous cell carcinomas of the lung and head and neck, with no differential expression of the two transcripts between normal and malignant tissue (Cataltepe et al., 2000) . Conversely, Kishimoto et al. (2001) describe the over-expression of SCCA1 and 2 in an adenoid squamous cell carcinoma cell line derived from the maxillary sinus. In this study, we describe the overrepresentation of SCCA1 and 2 in lung tumours, compared to corresponding normal tissue, in 15/35 patients. We also observed that SCCA2 expression appeared to be specific to the tumour samples and was detected in both squamous carcinomas and adenocarcinomas. Higher relative levels of SCCA2 to 1 have been described in malignant squamous tissues (Murakami et al., 2000) and several groups have suggested that the ratio of SCCA2 to 1 may be used as a marker for squamous cell carcinoma (Hamada et al., 2001; Stenman et al., 2001) . The results of this study suggest that overrepresentation of both SCCA1 and 2 occurs in NSCLC and that SCCA2 may be a useful, perhaps specific, marker of both squamous carcinoma and adenocarcinoma.
Hurpin was originally cloned from a keratinocyte cDNA library and inhibits cathepsins L and K (Jayakumar et al., 2003) . There is little information on the normal expression pattern or role of hurpin, although it has been reported that the gene is downregulated in head and neck cancer (Nakashima et al., 2000) . In this study, hurpin was over-represented in 13/35 NSCLC patients and transcripts were not detected in normal lung tissues. Plasminogen activator inhibitor 2 (pAI-2) inhibits the serine proteases urokinase-type and tissue-type plasminogen activator (uPA and tPA, respectively). However, high pAI-2 levels are associated with aggressive disease in colorectal cancer (Verspaget et al., 1995) and in bladder cancer cell lines, pAI-2 expression correlates with tumour stage and with a low overall survival (Champelovier et al., 2002) . Paradoxically, in breast cancer, high levels of pAI-2 have been reported to be a favourable prognostic marker (Duggan et al., 1997) and in vitro pAI-2 expression can inhibit cancer cell invasion and metastasis (Mueller et al., 1995) . In this study, pAI-2 was over-represented in 14/35 NSCLCs compared to corresponding normal lung. Megsin is a mesangial cellpredominant gene. Little is known about the function of this gene beyond the observation that it appears to control the proliferation and differentiation of mesangial cells (Miyata et al., 2002) . In this study, megsin over-representation was observed in 18/35 NSCLCs compared to normal tissue from the same patient. In some cases, pAI-2 and megsin transcripts were detected in normal tissue sample but not the matched tumour.
The most frequently differentially expressed of the genes analysed was maspin (26/35, 74% of tumours). Strikingly, in the absence of maspin expression, none of the other serpins showed over-representation in any patient. It is possible that regulatory systems or genomic damage events governing the expression of this gene, the most proximal of the serpin cluster, may affect the transcriptional regulation of the other sequences in the region. Given this observation, we therefore focused and extended our expression analysis to examine maspin levels in normal, neoplastic and preneoplastic tissues.
Maspin has long been considered to be a tumour suppressor gene. It was originally identified by subtractive hybridization as a breast tumour under-represented sequence (Zou et al., 1994) . While the 42 kDa maspin protein shows extensive homology to other serpins (Potempa et al., 1994) , a clear inhibitory role has yet to be demonstrated. Functional investigations, based on various model systems, have consistently suggested that expression of the 42 kDa protein is linked to a reduced ability of cells to move, invade or metastasize (Shi et al., 2001; Bass et al., 2002; Abraham et al., 2003) . Further supporting the tumour suppressor argument, it has been suggested that maspin expression may be directly induced by p53 (Zou et al., 2000) . However, this straightforward picture has recently been complicated by studies that have suggested that the expression of maspin in tumours predicts a poor clinical outcome in breast (Umekita et al., 2002) and ovarian (Sood et al., 2002) cancer. Such associations suggest that the role of maspin in disease biology may be more complex than initially envisaged. Our observation of frequent and strong expression of maspin in NSCLC, particularly squamous cell carcinomas, adds to this confusion, especially as we would expect the majority of such tumours to carry TP53 mutations (Fujita et al., 1999) .
Our observations raise the possibility that maspin expression might be exploited as a sputum immunodiagnostic target, one which might find particular application in the detection of the centrally located squamous tumours that are more difficult to identify by spiral CT. To begin to explore this possibility and in an attempt to improve our understanding of the significance of high levels of maspin in tumours, we investigated expression at multiple bronchial sites using an extensively characterized monoclonal antibody (ReisFilho et al., 2002; Mohsin et al., 2003) . In histologically non-neoplastic lung tissue, maspin was not expressed in the overwhelming majority of cells: hence, the negative scoring in RT-PCR and Western assays. However, within the tissue sections, at almost all non-neoplastic epithelial sites within the sampled airways, strong nuclear staining of the basal epithelial cells coupled with a lack of expression in the superficial differentiated columnar cells was detected. Our data suggest that this is the normal pattern of expression of this gene in the lung. The basal cells are multipotent reserve cells that retain the capacity to generate the various differentiated cell types of the airway epithelium. NSCLCs arise from a component(s) of this airway epithelium and it is generally possible to identify a range of pre-neoplastic lesions in the bronchial epithelia of patients, particularly smokers (Betticher et al., 1997; Ratschiller et al., 2003) . Examination of multiple tumour-free sites from 20 patients allowed us to make two potentially significant observations related to the pathological expression of maspin. Firstly, at few sites, a number of patients showed intense staining of the histologically nonneoplastic, superficial differentiated cells of the epithelial layer. Studies of genetic damage and clonality in such maspin-expressing epithelia would clearly add to our understanding of the significance of such observations. Secondly, the atypical cells of preneoplastic lesions frequently showed strong staining for maspin. It is interesting to note in this context that an upregulation of maspin expression has been reported to occur prior to the premalignant to malignant transition of prostatic epithelia (Pierson et al., 2002) .
Such results, consistent with a role for maspin in driving aspects of the neoplastic phenotype, do not necessarily conflict with the functional data which indicates that expression of this gene reduces the ability of cells to invade and metastasize. Indeed, although only a limited number of patients have been studied and caution must be exercised when interpreting such small sets of data, survival and relapse associations suggest that strong expression of maspin in the primary tumour is a good prognostic factor, a conclusion that would be consistent with a reduced tendency towards early metastasis. However, such conclusions do not exclude the possibility that maspin expression, by reducing motility and invasion, might not promote other aspects of neoplastic cell growth. This hypothesis would be consistent with the inappropriate expression of the gene in early preneoplastic lesions. Detailed evaluation of whether maspin expression might be a useful prognostic or diagnostic factor will require more extensive studies with large numbers of patients.
We must also consider that the identification of multiple isoforms of the maspin protein in this study might indicate a greater complexity of function than previously envisaged. We currently have no data suggesting that the maspin transcript is alternatively spliced in NSCLC cells. This perhaps indicates that the smaller isoform is generated by post-translational processing of the protein. In this respect, it is interesting to note that cleavage of maspin at its exposed reactive site loop (RSL) would generate a peptide of the size of the smaller isoforms observed in NSCLC tissue extracts (Pemberton et al., 1995) . Whether this hypothesis is true and whether the cleavage of the molecule is functionally important will require further testing. A second related aspect that we must consider is why the efficiency of detection of the two isoforms varied according to whether SDS was incorporated in the transfer buffer (TB). When proteins are laterally transferred in conventional (SDS-free) Western buffer, there is a gradual reduction in solubility of the proteins as SDS is stripped away. Generally, this is an issue only for large proteins that transfer very slowly and that may consequently become trapped in the gel. The incorporation of SDS in the TB minimizes this effect, maintaining over time the solubility of the transferring proteins. However, having SDS in this buffer can reduce the binding of some proteins to the Western membrane. There are therefore two reasons why we might see this additional immunoreactive protein band when SDS is incorporated into the TB: firstly, the solubility of the smaller isoform might normally be very low and improved by maintaining high levels of SDS during transfer and secondly, the relative binding efficiencies of the two isoforms to the PVDF membrane may be altered by the presence of SDS. Either explanation argues for a difference in the biochemical properties of the maspin isoforms.
Furthermore, as suggested by Sood et al. (2002) the particular subcellular localization of the protein in different cell types/situations might be associated with specific function. The investigation of such possibilities gains considerable importance given the suggestion that maspin may modulate the levels of urokinase plasminogen activator, an anticancer drug target currently under clinical evaluation (Biliran and Sheng, 2001 ).
Materials and methods
Clinical samples
Two independent series of tissues were used in this study, collected from clinical centres in Liverpool and Bern as part of wider ethically approved programmes being undertaken at the Roy Castle Centre and University of Bern. The first series (Liverpool) comprised tumour and matched normal lung (>10 cm from primary) from 35 resectable-staged NSCLC patients (25 men, 10 women, median age 67 years, range 49-87). In all, 18 patients were in stage I, 10 stage II and seven stage III. There were: 18 adenocarcinomas, 15 squamous cell carcinomas, one large cell carcinoma and one undifferentiated NSCLC. No survival data were available for this patient group. The second series comprising tumour samples and matched bronchial epithelia from six independent, tumour-free sites were collected prospectively from consecutive patients (37 men, 11 women, median age 65.3 years, range 30.6-80.7) who underwent resection of staged-resectable NSCLC at the University Hospital of Bern, Switzerland (segmentectomy (n ¼ 2), lobectomy (n ¼ 32) or pneumonectomy (n ¼ 14)). A total of 17 patients were in stage I, 12 in stage II and 19 in stage III. Patients were asked about their smoking habits and whether they had ceased smoking. All tumours were classified according to the standard criteria of the WHO by the local pathologists, reviewed then by our pathologist (MG): there were 20 squamous carcinomas, 24 adenocarcinomas, three large cell carcinomas and one poorly differentiated NSCLC. Tumour size was measured by the pathologists on the fresh specimen. Of 48 patients, 26 are alive with a median observation time of 16 months (range 0.5-33). The specimens were processed in formalin and embedded in paraffin for IHC.
RNA and DNA extraction
Total RNA was extracted from 20 Â 40 mm sections of frozen tumour and normal tissues using a standard TRIzol (Life Technologies), protocol . Following ethanol precipitation, the RNA was resuspended in 100 ml of RNase-free water and stored at À701C. RNA was run on an Agilent 2100 Bioanalyser RNA Chip (Agilent Technologies), to confirm its integrity. Yields averaged 125 mg of total RNA from the tumours and 36 mg from the normal tissue. DNA was extracted from 10 Â 40 mm frozen sections, using a standard SDS lysis/phenol extraction procedure . Sections of 5 mm were cut adjacent to both RNA and DNA sections and were stained to show tumour histology and to estimate the overall percentage of overt viable tumour cells.
RT-PCR, comparative multiplex RT-PCR and PCR
Reverse transcription was performed with a Reverse Transcription System (Promega), from 1 mg of total RNA, in a 20 ml synthesis. RT-PCR reactions containing 1 ml of cDNA, two primers (0.5 mg each), 1 Â Taq reaction buffer (Roche), 200 mM dNTPs (Roche) and 1 U of Taq polymerase (Roche), in a total of 50 ml were assembled and cycled 30 times in a PE Applied Biosystems GeneAmp PCR System 9700 machine at 581C for 1 min, 741C for 1 min and 941C for 1 min, with an initial denaturation of 2 min at 941C and a final cycle of 581C for 1 min, 741C for 3 min. Reaction products were visualized on 2.5% agarose gels run in TAE. In cmRT-PCR, competitive reactions using four instead of two primers were assembled to amplify concurrently a test and a control cDNA, to be able to relate levels of the test transcript to those of a constant control in any one reaction. Transcript-specific primers (experimentally confirmed, intron-spanning) were used in all cases. For SCCA1 and 2, the primer set used amplified both transcripts concurrently.
The results of cmRT-PCR were quantified on an Agilent 2100 Bioanalyser using DNA 1000 chips (Agilent Biotechnologies). PCR products with a peak height of X2 were considered to indicate expression of a gene because these bands were unequivocally visible by eye when the samples were run on standard 2.5% agarose gels. Peak heights of the test genes were divided by those of the control gene within each sample. The comparative value in the patient tumour tissue was divided by that from the matched normal to calculate the fold difference in expression of the test gene in each patient. Where no test-gene product was seen in normal tissue and where a product was detected in tumour, the fold-change was therefore infinite. While in many cases, test gene expression was not detected in normal lung, a differential expression of the test gene of X2-fold in the tumour was considered to indicate a relative over-representation of that gene in the tumour. It should be noted that this procedure is only semiquantitative and does not reflect on absolute expression levels of the test gene mRNA.
Primers
Primer sequences are available on request (or see Roy Castle Foundation website: http://www.roycastle. org.uk/research/). Primers to hypothetical protein KIAA0228 (Accession number: D86981) and to phosphatidylinositol transfer protein (Accession number: D30037), which are levelly expressed in lung carcinomas compared to matched normal lung tissue, were used as control primers in cmRT-PCR.
RFLP analysis of SCCA1/2
Primers common to both gene products (100% identity) were used to determine the relative contribution of SCCA1 and 2 using an RFLP-type analysis. SCCA1/2 gene products were amplified using RT-PCR. The resulting RT-PCR products were digested with the restriction enzyme EcoRV. Digestion products were run on 2.5% agarose and on an Agilent 2100 Bioanalyser DNA 1000 chip, to quantify the results.
Western analysis
A standard Western protocol was used to analyse protein levels of maspin. Briefly, 10 Â 40 mm sections were lysed using 1 ml of PE buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% w/v SDS, 0.5% v/v NP40 containing one protease inhibitor cocktail tablet (Roche) per 50 ml). An equal volume of 2 Â Tracking dye (100 mM Tris-HCl pH 6.8, 16% v/v glycerol, 3% w/v SDS, 8% v/v b-mercaptoethanol, 0.04% w/v bromophenol blue) was added to the lysate and the mixture boiled for 10 min. Equal amounts of protein from the normal and tumour samples of each patient were loaded onto 12% polyacrylamide gels and electroblotted overnight onto Immobilon-P membrane (Millipore) in standard Tris-base (25 mM), glycine (195 mM), 20% (v/v) methanol (ÀSDS), or Tris-base (25 mM) glycine (195 mM), 10% (v/v) methanol, 0.1% (w/v) SDS ( þ SDS) transfer buffer. Membranes were blocked for 4 h in 4% milk powder in PBS containing 0.05% v/ v Tween-20 (PBST). A 1 : 500 dilution of the primary maspin mouse monoclonal antibody (G167-70, Pharmingen) was then applied and incubated for 1 h. Following PBST washes, a 1 : 1000 dilution of goat anti-mouse secondary antibody (Dako) was added to the membrane for 1 h. Following further PBST washes, secondary antibody binding was detected using the ECL þ Plus enhanced chemiluminescence detection system (Amersham).
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections of 5 mm were dewaxed in xylene for 30 min, followed by rehydration through a series of graded ethanols to water. Antigens were retrieved using a 15-min microwave treatment in Vector unmasking solution (10 mM sodium citrate buffer, pH 6). Slides were washed in standing and running water for 15 and 5 min, respectively, prior to loading onto a Dako Autostainer. Endogenous peroxidase was blocked by a 15-min incubation in 3% v/v H 2 O 2 . Sections were then incubated for 60 min in a 1 in 500 dilution of the primary maspin mouse monoclonal antibody (G167-70, Pharmingen). This was followed by detection of specific staining with the Dako LSAB2 HRP system with DAB (diaminobenzidine) substrate. Slides were counterstained in haematoxylin/Scotts tap water and dehydrated through a series of graded ethanols to xylene. Sections were mounted in DPX and visualized. In negative control sections, the primary antibody was replaced with diluent. A tumour that strongly expressed maspin was used as a positive control on all autostainer runs.
The sections were reviewed by our pathologist (MG) in a blinded fashion, considering histology, grading of differentiation and maspin staining. Epithelial changes were graded according to the criteria reviewed by Travis et al. (1999) . Squamous metaplasia is the first clear-cut morphological change in the respiratory epithelium induced by smoking. We grouped epithelial sites into non-neoplastic (histologically normal and hyperplastic) and premalignant (metaplastic and dysplastic). In detail, regarding maspin staining, the following criteria were used for cytoplasmic and/or nuclear staining, for the intensity À, þ , þ þ , þ þ þ and for the frequency 0-5, 5-50, 50-100%. For data grouping, a bronchial site was considered to be positive for nuclear and cytoplasmic staining if >5% of the apical epithelial cells were scored with a þ þ to þ þ þ intensity.
Statistical analyses w
2 analysis was used to compare firstly the incidence of overrepresentation of particular transcripts with tumour histology and secondly, the frequency of nuclear staining for maspin in normal (normal and hyperplastic) versus preneoplastic (metaplastic/dysplastic) epithelia. Patients were further placed into two groups according to their maspin expression and overall survival, and remission duration was analysed by the KaplanMeier survivor function estimates.
